FORMULATION AND CHARACTERIZATION OF CHRONO MODULATED COLON TARGETED DRUG DELIVERY OF VEDOLIZUMAB (ENTYVIO) DRUG

Abstract

This study focuses on the development and characterization of a novel chrono-modulated colon-targeted drug delivery system for Vedolizumab (Entyvio), an important drug used for inflammatory bowel disease. The formulation aims to optimize drug release timing to synchronize with the circadian rhythm of the gastrointestinal tract, enhancing therapeutic efficacy and reducing potential side effects. The formulation process involves the encapsulation of Vedolizumab in specialized carriers designed to delay drug release until reaching the colon. Various physicochemical parameters, such as bulk density, tapped density, compressibility index, and angle of repose, are evaluated to ensure optimal formulation characteristics. In vitro dissolution studies are conducted to assess drug release profiles at different time intervals, mimicking the circadian rhythm. Results demonstrate the successful development of the chrono-modulated formulation, with promising delayed drug release in line with the desired timing for colonic drug delivery. Variations in drug release kinetics among batches highlight the need for rigorous quality control measures. Additionally, accelerated stability studies suggest the formulation's stability under defined conditions, although further investigations are warranted to assess long-term stability. This research contributes to the advancement of targeted drug delivery systems and offers potential benefits for patients requiring Vedolizumab therapy. The findings underscore the importance of optimizing drug release timing for enhanced therapeutic outcomes and serve as a foundation for future studies in the field of chrono-modulated drug delivery systems.